期刊文献+

Low-dose testosterone treatment decreases oxidative damage in TM3 Leydig cells 被引量:3

低剂量睾酮疗法降低TM3睾丸间质细胞的氧化损伤
下载PDF
导出
摘要 Testosterone replacement therapy has benefits for aging men and those with hypogonadism. However, the effects of exogenous testosterone on Leydig cells are still unclear and need to be clarified. In this report, we demonstrate that testosterone supplementation can reduce oxidative damage in Leydig cells. The TM3 Leydig cell line was used as an in vitrocell model in this study. Cytoprotective effects were identified with 100-nmol l-1 testosterone treatment, but cytotoxic effects were found with ≥ 500-nmol l-1 testosterone supplementation. Significantly reduced reactive oxygen species (ROS) generation, lipid peroxide contents and hypoxia induction factor (HIF)-lα stabilization and activation were found with lO0-nmol 1-1 testosterone treatment. There was a 1.72-fold increase in ROS generation in the 500-nmol l-1 compared to the lO0-nmol l-1 testosterone treatment. A 1.58-fold increase in steroidogenic acute regulatory protein (STAR) expression was found in 50-nmol l-1 testosterone-treated cells (P〈0.01). Chemically induced hypoxia was attenuated by testosterone supplementation. Leydig cells treated with low-dose testosterone supplementation showed cytoprotection by decreasing ROS and lipid peroxides, increasing StAR expression and relieving hypoxia stress as demonstrated by HIF-1α stabilization. Increased oxidative damage was found with ≥ 500-nmol l-1 testosterone manipulation. The mechanism governing the differential dose effects of testosterone on Leydig cells needs further investigation in order to shed light on testosterone replacement therapy. Testosterone replacement therapy has benefits for aging men and those with hypogonadism. However, the effects of exogenous testosterone on Leydig cells are still unclear and need to be clarified. In this report, we demonstrate that testosterone supplementation can reduce oxidative damage in Leydig cells. The TM3 Leydig cell line was used as an in vitrocell model in this study. Cytoprotective effects were identified with 100-nmol l-1 testosterone treatment, but cytotoxic effects were found with ≥ 500-nmol l-1 testosterone supplementation. Significantly reduced reactive oxygen species (ROS) generation, lipid peroxide contents and hypoxia induction factor (HIF)-lα stabilization and activation were found with lO0-nmol 1-1 testosterone treatment. There was a 1.72-fold increase in ROS generation in the 500-nmol l-1 compared to the lO0-nmol l-1 testosterone treatment. A 1.58-fold increase in steroidogenic acute regulatory protein (STAR) expression was found in 50-nmol l-1 testosterone-treated cells (P〈0.01). Chemically induced hypoxia was attenuated by testosterone supplementation. Leydig cells treated with low-dose testosterone supplementation showed cytoprotection by decreasing ROS and lipid peroxides, increasing StAR expression and relieving hypoxia stress as demonstrated by HIF-1α stabilization. Increased oxidative damage was found with ≥ 500-nmol l-1 testosterone manipulation. The mechanism governing the differential dose effects of testosterone on Leydig cells needs further investigation in order to shed light on testosterone replacement therapy.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2011年第3期432-437,512,共7页 亚洲男性学杂志(英文版)
关键词 Leydig cells oxidative damage reactive oxygen species TESTOSTERONE Leydig cells oxidative damage reactive oxygen species testosterone
  • 相关文献

参考文献4

二级参考文献178

  • 1Liu PY,Beilin J,Meier C,Nguyen TV,Center JR,et al.Age-related changes in serum testosterone and sex hormone binding globulin in Australian men:longitudinal analyses of two geographically separate regional cohorts.J Clin Endocrinol Metab 2007;92:3599-603.
  • 2Yassin AA,Saad F,Gooren LJ.Metabolic syndrome,testosterone deficiency and erectile dysfunction never come alone.Andrologia 2008;40:259-64.
  • 3Tenover JL.Testosterone replacement therapy in older adult men.Int J Androl 1999;22:300-6.
  • 4Traish AM,Saad F,Guay A.The dark side of testosterone deficiency:II.Type 2 diabetes and insulin resistance.J Androl 2009;30:23-32.
  • 5Traish AM,Feeley RJ,Guay A.Mechanisms of obesity and related pathologies:androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction.Febs J 2009;276:5755-67.
  • 6Saad F,Gooren L.The role of testosterone in the metabolic syndrome:a review.J Steroid Biochem Mol Biol 2009;114:40-3.
  • 7Traish AM,Goldstein I,Kim NN.Testosterone and erectile function:from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.Eur Urol 2007;52:54-70.
  • 8Mc Vary K.Lower urinary tract symptoms and sexual dysfunction:epidemiology and pathophysiology.BJU Int 2006;97 Suppl 2:23-8;discussion 44-5.
  • 9Haider A,Gooren LJ,Padungtod P,Sand F.Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men.Andrologia 2009;41:7-13.
  • 10Handelsman DJ,Liu PY.Andropause:invention,prevention,rejuvenation.Trends Endocrinol Metab 2005;16:39-45.

共引文献24

同被引文献9

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部